Hearing loss in children with osteogenesis imperfecta
- PMID: 10923226
- DOI: 10.1007/s004310051322
Hearing loss in children with osteogenesis imperfecta
Abstract
Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue. Progressive hearing loss is one of the principal symptoms of OI, affecting about 50% of adult patients. Hearing loss may also occur in childhood and results in additional disability in education and psychosocial adaptation and aggravates the physical handicap. This can be avoided by appropriate otological and audiological treatment. In a nationwide search, 254 Finnish patients with OI were identified indicating a prevalence of 4.9/100,000. Of the 60 children, 45 aged between 4 and 16 years accepting to participate the study on hearing, were evaluated by a questionnaire and clinical audiometry. Hearing loss was defined as pure tone average (PTA0.5-2 kHz) more than 20 dB hearing level (HL). A clinical geneticist determined the type of OI among the 45 patients. Two sporadic OI cases with conductive hearing loss were ascertained (4.4%): An 11-year-old girl with type IV OI with a PTA0.5-2 kHz of 35/40 dB HL and a 15-year-old boy with type IV OI with a PTA0.5-2 kHz of 27/18 dB HL. In addition, a 6-year-old girl with familial OI type I had either a congenital sensorineural deafness or early progressive deafness with PTA0.5-2 kHz of 97/103 dB HL, probably of unrelated aetiology.
Conclusion: Hearing loss in children with osteogenesis imperfecta is less frequent than generally suspected. Nevertheless, it is recommended that audiometry is performed in children with osteogenesis imperfecta even without symptoms of hearing loss at the age of 10 years, and repeated every 3 years thereafter.
Similar articles
-
[Hearing loss in osteogenesis imperfecta--casuistic demonstration].Otolaryngol Pol. 2006;60(1):51-3. Otolaryngol Pol. 2006. PMID: 16821542 Polish.
-
Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey.Ann Otol Rhinol Laryngol. 2002 Oct;111(10):939-46. doi: 10.1177/000348940211101014. Ann Otol Rhinol Laryngol. 2002. PMID: 12389865
-
Audiologic phenotype of osteogenesis imperfecta: use in clinical differentiation.Otol Neurotol. 2012 Feb;33(2):115-22. doi: 10.1097/MAO.0b013e31823e28e9. Otol Neurotol. 2012. PMID: 22143304
-
Hearing impairment and osteogenesis imperfecta: Literature review.Eur Ann Otorhinolaryngol Head Neck Dis. 2019 Oct;136(5):379-383. doi: 10.1016/j.anorl.2019.05.004. Epub 2019 Jun 13. Eur Ann Otorhinolaryngol Head Neck Dis. 2019. PMID: 31202667 Review.
-
Hearing loss (in nonoperated ears) in relation to age in osteogenesis imperfecta type I.Ann Otol Rhinol Laryngol. 1997 Jul;106(7 Pt 1):575-82. doi: 10.1177/000348949710600709. Ann Otol Rhinol Laryngol. 1997. PMID: 9228859 Review.
Cited by
-
Hearing impairment amongst people with Osteogenesis Imperfecta in Germany.Eur Arch Otorhinolaryngol. 2024 Sep 27. doi: 10.1007/s00405-024-08983-5. Online ahead of print. Eur Arch Otorhinolaryngol. 2024. PMID: 39333311
-
Treatments for hearing loss in osteogenesis imperfecta: a systematic review and meta-analysis on their efficacy.Sci Rep. 2022 Oct 12;12(1):17125. doi: 10.1038/s41598-022-20169-9. Sci Rep. 2022. PMID: 36224204 Free PMC article.
-
Ocular characteristics and complications in patients with osteogenesis imperfecta: a systematic review.Acta Ophthalmol. 2022 Feb;100(1):e16-e28. doi: 10.1111/aos.14882. Epub 2021 May 19. Acta Ophthalmol. 2022. PMID: 34009739 Free PMC article.
-
Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.Endocr Rev. 2022 Jan 12;43(1):61-90. doi: 10.1210/endrev/bnab017. Endocr Rev. 2022. PMID: 34007986 Free PMC article. Review.
-
Oral Bisphosphonate Therapy for Osteogenesis Imperfecta: A Systematic Review and Meta-Analysis of Six Randomized Placebo-Controlled Trials.Orthop Surg. 2020 Aug;12(4):1293-1303. doi: 10.1111/os.12611. Epub 2020 Jun 26. Orthop Surg. 2020. PMID: 32589343 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
